Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 1Graft vs Host Disease 1

Interventions

Cytarabine 906Cyclophosphamide 900fludarabine 525venetoclax 489fludarabine phosphate 468Azacitidine 461Rituximab 431Methotrexate 420Etoposide 320Filgrastim 299Busulfan 296Dexamethasone 287Vincristine 286Daunorubicin 284Peripheral Blood Stem Cell Transplantation 258Whole-Body Irradiation 243Mycophenolic Acid 232Decitabine 230Granulocyte Colony-Stimulating Factor 227Tacrolimus 220Imatinib Mesylate 211Idarubicin 205Melphalan 202Cyclosporine 182Doxorubicin 178Radiotherapy 169Prednisone 164Dasatinib 163Mitoxantrone 161Lenalidomide 160

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
eritoran × Other hematologic neoplasm × Clear all
NCT00756912 2014-07-11

A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors

Eisai Inc.

Phase 1 Terminated
30 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡